| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1640.1B | ¥1584.8B | +3.5% |
| Operating Income | ¥91.3B | ¥109.3B | -16.5% |
| Ordinary Income | ¥118.8B | ¥135.1B | -12.0% |
| Net Income | ¥64.7B | ¥81.4B | -21.2% |
| ROE | 3.7% | 4.5% | - |
FY2025 Q3 cumulative results show revenue growth but significant profit decline. Revenue reached 164.0 billion yen (YoY +3.5%, +5.5 billion yen), while operating income decreased to 9.1 billion yen (YoY -16.5%, -1.8 billion yen). Ordinary income declined to 11.9 billion yen (-12.0%), and net income attributable to owners fell to 6.4 billion yen (-21.2% from 8.1 billion yen). The company revised its full-year guidance downward, reducing revenue forecast by 5.0 billion yen to 235.0 billion yen and operating income by 4.0 billion yen to 20.0 billion yen, reflecting domestic capital investment restraint and North American monitor deal slowdown.
Revenue increased 3.5% driven by overseas expansion, achieving double-digit growth in North America, Europe, and Asia-Pacific. Excluding foreign exchange effects and Adtec Medical consolidation, overseas sales grew 7% in real terms. Domestic revenue declined 0.9% as capital investment suppression in government hospitals and AED inventory adjustments at distributors offset steady consumables and service revenue.
Gross profit margin maintained 51.9%, but operating income dropped 16.5% as selling, general and administrative expenses increased substantially due to wage hikes and R&D investment expansion. SG&A expenses reached 75.9 billion yen, compressing operating margin to 5.6% from prior year's 6.9%. Operating leverage failed to materialize despite revenue growth.
The gap between operating income (9.1 billion yen) and ordinary income (11.9 billion yen) of 2.8 billion yen primarily reflects foreign exchange gains of 2.5 billion yen in non-operating income, indicating significant FX sensitivity. Extraordinary losses of 2.4 billion yen, mainly early retirement premium payments, further compressed net income to 6.4 billion yen. The effective tax rate stood at 34.6%, reducing pretax income of 9.9 billion yen to net income of 6.4 billion yen.
This quarter exhibits a "revenue up, profit down" pattern, driven by SG&A inflation outpacing revenue growth and non-recurring restructuring costs, partially offset by favorable FX impacts.
By geographic segment, domestic operations generated 100.2 billion yen (-0.9%) with weakness concentrated in medical equipment due to capital budget constraints at government hospitals. AED sales declined on distributor inventory correction. However, consumables and service businesses remained resilient.
Overseas operations, representing 39% of total revenue, achieved 63.8 billion yen (+11.3%), serving as the primary growth driver. North America delivered double-digit growth with strong demand for physiological measurement equipment and treatment devices. Europe expanded primarily in Italy, Turkey, and the Netherlands. Asia-Pacific and Middle East/Africa regions showed robust momentum. Adjusting for FX and Adtec Medical consolidation, real overseas growth reached approximately 7%.
By product category, Physiological Measurement Equipment recorded 26.1 billion yen (+2.9%) with cardiac catheterization lab systems performing strongly. Patient Monitoring Equipment declined to 30.7 billion yen (-4.3%) as telemetry transmitters, which had been strong in the prior year, contracted, though bedside monitors remained stable. Treatment Equipment fell to 21.2 billion yen (-5.1%) as ablation catheters, ventilators, and AEDs underperformed. Other category grew to 22.1 billion yen (+3.9%) supported by installation work, maintenance services, laboratory analyzers, and reagents.
Operating profit analysis by segment was not disclosed in available materials. However, the overseas segment's growth contribution is evident, while domestic market headwinds limited overall profitability improvement.
Profitability: ROE 3.7% (prior year 4.5%), ROA 3.3% (industry median 3.3%), Operating Margin 5.6% (prior 6.9%, industry median 8.3%), Net Profit Margin 3.9% (industry median 6.3%). DuPont analysis reveals ROE deterioration primarily stems from net profit margin compression, with asset turnover at 0.665x and financial leverage at 1.43x.
Cash Quality: Operating CF to Net Income ratio 1.95x indicating strong cash-backed earnings quality. However, working capital efficiency shows severe deterioration with Days Sales Outstanding at 128 days (industry median 83 days), Days Inventory Outstanding at 287 days (industry median 109 days), and Cash Conversion Cycle at 325 days (industry median 108 days).
Investment: CapEx to Depreciation ratio 1.25x (CapEx 5.9 billion yen, D&A 4.7 billion yen) indicating growth phase investment. Major capital allocation includes Tsurugashima new factory construction with total planned investment of 11.0 billion yen through FY2027.
Financial Health: Equity Ratio 69.9% (prior 70.2%, industry median 63.8%), Current Ratio 364.2% (industry median 284%), Quick Ratio 284.5%, Net Debt to EBITDA 1.84x. Financial structure remains highly conservative with ample liquidity.
Operating CF: 12.5 billion yen (1.95x of Net Income), demonstrating robust cash generation capability well above the 1.0x threshold for healthy cash-backed earnings.
Investing CF: -6.5 billion yen, primarily comprising CapEx of 5.9 billion yen for facility investments including Tsurugashima new factory (3.2 billion yen planned in FY2025, part of total 11.0 billion yen project through FY2027).
Financing CF: -2.7 billion yen including share buybacks of 2.7 billion yen. Short-term borrowings decreased dramatically from 26.0 billion yen to 0.05 billion yen (-99.8%), while cash and deposits increased from 28.4 billion yen to 38.0 billion yen (+33.7%), indicating debt refinancing and liquidity enhancement.
FCF: 6.0 billion yen (Operating CF 12.5 billion yen minus CapEx 4.7 billion yen using conservative calculation), providing coverage for capital allocation including dividends and buybacks.
Cash generation: Adequate. Operating CF remains strong, but working capital inefficiencies (elevated DSO and DIO) constrain optimal cash conversion. Free cash flow after CapEx covers shareholder returns, though sustainability warrants monitoring given high payout commitments.
Ordinary income of 11.9 billion yen exceeded operating income of 9.1 billion yen by 2.8 billion yen (30% premium), primarily reflecting foreign exchange gains of 2.5 billion yen in non-operating income. This represents approximately 27% of operating income, highlighting significant FX sensitivity and indicating a material non-recurring or volatile component supporting profitability.
Extraordinary losses totaling 2.4 billion yen, primarily early retirement premium payments, represent a clear non-recurring factor that compressed net income by 24%. These restructuring costs are one-time in nature but signal ongoing efforts to optimize cost structure.
The gap between pretax income (9.9 billion yen) and net income (6.4 billion yen) reflects an effective tax rate of 34.6%, which is within normal range and does not indicate extraordinary tax impacts.
Accrual quality: Operating CF to Net Income ratio of 1.95x indicates earnings are well-backed by cash, mitigating concerns about accrual-based earnings inflation. However, the significant deterioration in working capital efficiency (DSO 128 days, DIO 287 days) suggests that while current period cash generation is healthy, future cash conversion may face pressure if receivables and inventory continue to accumulate. The company carries goodwill of 11.3 billion yen and intangible assets of 25.5 billion yen (combined 15% of total assets), requiring monitoring for potential future impairment risks.
Full-year guidance revised downward: Revenue reduced from 240.0 billion yen to 235.0 billion yen (-5.0 billion yen, -2.1%), Operating Income from 24.0 billion yen to 20.0 billion yen (-4.0 billion yen, -16.7%), Ordinary Income from 22.0 billion yen to 22.0 billion yen (unchanged), Net Income from 12.5 billion yen to 12.5 billion yen (unchanged).
Q3 cumulative progress rate: Revenue 69.8% (235.0 billion yen guidance), Operating Income 45.7% (20.0 billion yen guidance), Ordinary Income 54.0% (22.0 billion yen guidance). Against standard quarterly progression (Q3=75% for revenue, 75% for profits), revenue tracking is 5.2 percentage points below, while operating income lags significantly at 29.3 percentage points below standard progression.
The substantial shortfall in operating income progression indicates Q4 is expected to deliver approximately 10.9 billion yen in operating income (119% of Q3 cumulative), requiring exceptional Q4 performance to achieve guidance. This assumes strong seasonal year-end demand for IT system installations and successful cost control measures including gross margin improvement to 52% range and SG&A restraint.
Key revision drivers: Domestic capital investment restraint at government hospitals beyond initial expectations, AED distributor inventory correction, cautious North American patient monitoring deal decision processes, and regulatory compliance delays in Asia-Pacific markets extending delivery timelines. Management plans to focus on consumables, services, and year-end IT system deliveries domestically, while concentrating on shipments and installations overseas to maintain real growth momentum.
Interim dividend: 15.0 yen per share (Q2). Year-end dividend guidance: 16.0 yen per share. Total annual dividend: 16.0 yen per share based on full-year guidance.
Calculated payout ratio: 82.7% based on full-year net income guidance of 12.5 billion yen and approximately 648 million shares outstanding (dividend amount approximately 10.3 billion yen). This represents an elevated payout ratio requiring monitoring for sustainability.
Share buybacks: 2.7 billion yen executed in Q3 cumulative period. Combined with projected annual dividends of approximately 10.3 billion yen, total shareholder returns reach approximately 13.0 billion yen.
Total return ratio: Approximately 104% (total returns 13.0 billion yen / net income 12.5 billion yen guidance), exceeding 100% and indicating aggressive capital return policy. This is supported by strong operating CF of 12.5 billion yen (Q3 cumulative) and FCF of 6.0 billion yen, but sustainability depends on maintaining cash generation amid working capital pressures and capital investment requirements including the 11.0 billion yen Tsurugashima factory project through FY2027.
FCF coverage: FCF of 6.0 billion yen provides coverage ratio of 1.13x against capital allocation needs (dividends plus buybacks), leaving limited cushion. The company's cash position increased to 38.0 billion yen (+33.7% YoY), providing buffer for shareholder returns, but the combination of high total return ratio, elevated working capital, and ongoing CapEx program warrants close monitoring of cash flow sustainability.
Near-term: Q4 domestic IT system year-end installation rush, consumables and service revenue momentum, North American patient monitoring deal closings, overseas shipment and installation acceleration to meet revised guidance, gross margin improvement initiatives targeting 52% range, and SG&A cost control measures.
Long-term: Phase II medium-term plan (FY2024-2028) targeting revenue CAGR 5%, operating margin 15%, and ROE 12% through product competitiveness enhancement and North American business expansion. Tsurugashima new factory completion (total investment 11.0 billion yen through FY2027) to enhance production capacity and efficiency. Overseas market share expansion particularly in North America where double-digit growth momentum continues. New product launches including advanced cardiac catheterization lab systems and next-generation patient monitors. Improvement in working capital efficiency to normalize DSO and DIO toward industry levels, potentially releasing significant cash.
Industry Position (Reference - Proprietary Analysis)
Profitability: ROE 3.7% (Industry Median 5.0%), ROA 3.3% (Industry Median 3.3%), Operating Margin 5.6% (Industry Median 8.3%), Net Profit Margin 3.9% (Industry Median 6.3%). The company's profitability metrics rank below industry median except for ROA which matches the median, indicating operational efficiency challenges relative to peers.
Financial Health: Equity Ratio 69.9% (Industry Median 63.8%), Current Ratio 364.2% (Industry Median 284%), Net Debt/EBITDA 1.84x (Industry Median -1.11x). Financial stability exceeds industry standards with above-median equity cushion and liquidity, though positive net debt position contrasts with industry's net cash position.
Efficiency: Asset Turnover 0.665x (Industry Median 0.58x), DSO 128 days (Industry Median 83 days), DIO 287 days (Industry Median 109 days), Cash Conversion Cycle 325 days (Industry Median 108 days). Asset turnover exceeds industry median, but working capital efficiency significantly underperforms with receivables and inventory cycles approximately 1.5x and 2.6x industry median respectively.
Growth: Revenue Growth 3.5% (Industry Median 2.7%), EPS Growth -21.2% (Industry Median 6%). Revenue growth exceeds industry median reflecting strong overseas expansion, but earnings growth lags substantially due to margin compression.
Returns: ROIC 3.8% (Industry Median 5.0%), FCF Yield 2% (Industry Median 2%). Return on invested capital trails industry median, consistent with elevated working capital and compressed margins.
Industry: Medical device manufacturing (n=98 companies), Comparison: FY2025 Q3 cumulative period, Source: Proprietary analysis.
Working Capital Deterioration: DSO of 128 days (vs. industry median 83 days) and DIO of 287 days (vs. industry median 109 days) represent 1.5x and 2.6x industry levels respectively, with CCC of 325 days indicating 10.8 months of revenue tied up in working capital. This creates significant cash conversion risk and potential for inventory obsolescence or bad debt, particularly given elevated product warranty reserves of 1.9 billion yen. Failure to normalize working capital could constrain cash generation and threaten dividend sustainability.
Foreign Exchange Volatility: FX gains of 2.5 billion yen represent 27% of operating income, indicating high sensitivity to currency fluctuations. A 5 yen/USD movement could materially impact profitability. While Q3 average rate of 148.6 yen/USD vs. 152.0 yen/USD prior year provided tailwind, Q4 assumption of 154 yen/USD suggests potential reversal. Overseas operations generate 39% of revenue, amplifying translation and transaction exposure.
Profitability Sustainability: Operating margin compressed to 5.6% from 6.9%, substantially below Phase II medium-term plan target of 15% and industry median of 8.3%. SG&A expenses increased faster than revenue despite only 3.5% sales growth, indicating negative operating leverage. Without successful cost structure reform and gross margin improvement to targeted 52% range, the company faces risk of further margin erosion. Combined with aggressive shareholder returns (total return ratio 104%), sustained profitability pressure could compromise both returns and growth investment capacity.
Working capital management is the critical determinant of cash flow sustainability. While operating CF remains robust at 1.95x net income, DSO of 128 days and DIO of 287 days represent severe inefficiency at 2.6x and 1.5x industry median respectively. Normalizing working capital to industry levels could release approximately 50-80 billion yen in cash, transforming the financial profile. Current CCC of 325 days essentially ties up nearly 11 months of revenue in operations, constraining return on invested capital to 3.8% vs. industry median 5.0% and management's mid-term targets.
Overseas growth momentum provides structural revenue support. North America, Europe, and Asia-Pacific achieved double-digit growth with 7% real growth excluding FX and M&A effects, demonstrating underlying business strength. With overseas operations contributing 39% of revenue and continuing expansion, the top-line growth trajectory of 3.5% (above industry median 2.7%) appears sustainable. However, translating revenue growth into profit improvement requires addressing the core issue: SG&A expenses outpacing sales growth, compressing operating margin to 5.6% from 6.9% and widening the gap to the industry median of 8.3%.
Capital allocation policy presents sustainability questions. Total return ratio exceeding 100% (dividends plus buybacks of approximately 13.0 billion yen vs. net income guidance 12.5 billion yen), payout ratio of 82.7%, and ongoing CapEx program totaling 11.0 billion yen for Tsurugashima factory through FY2027 create competing demands on cash. While current cash position of 38.0 billion yen and operating CF of 12.5 billion yen provide near-term support, the combination of elevated shareholder returns, growth investment requirements, and working capital inefficiency leaves limited financial flexibility. FCF coverage of 1.13x against capital allocation needs offers minimal cushion for execution shortfalls or external shocks.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
Nihon Kohden Corporation’s results for the third quarter of the fiscal year ending March 2026 showed higher revenue but lower earnings, with net sales of 1,640 billion yen (+3.5% YoY) and operating income of 9.1 billion yen (-16.5% YoY). Domestic revenue declined due to restrained capital investment in medical equipment and inventory adjustments at AED distributors, while overseas posted double-digit growth in North America, Europe, and Asia/Other regions. The main reasons for the decline in operating income were lower domestic revenue, wage increases, and higher SG&A expenses driven by increased R&D investment. Net income decreased to 6.4 billion yen (-21.2% YoY) due to recognition of a special loss of 2.4 billion yen for early retirement incentives. The full-year forecast was revised downward to net sales of 2,350 billion yen (downward revision of 5 billion yen from the previous forecast) and operating income of 20 billion yen (downward revision of 4 billion yen), with a policy to focus on sales of in-house products in Q4 to secure a gross margin in the 52% range and to restrain SG&A expenses.
Domestic net sales declined as budget restraints and deferrals for hospitals and clinics exceeded expectations, and AED sales fell below the prior-year level due to inventory adjustments at distributors. Overseas net sales were strong even excluding FX and the consolidation impact of Ad-Tech Medical, with a 7% increase on a real basis, led by North America, Europe, and Asia/Other regions. Operating income fell by 1.8 billion yen YoY due to higher SG&A (salaries and allowances +1.59 billion yen, amortization of goodwill +0.69 billion yen, depreciation +0.56 billion yen, R&D expenses +0.32 billion yen, etc.). The decline in gross margin in Q3 to 50.6% from 54.8% in the prior year and 47.3% two years ago was mainly due to cost increases, higher inventory valuation losses, and changes in product mix. In Q4, the company will focus on consumables and services, and on delivery and installation of year-end IT system deals, aiming to secure revenue on par with the prior-year quarter.
Full-year net sales were revised downward by 5 billion yen domestically to 2,350 billion yen, and operating income was revised downward by 4 billion yen to 20 billion yen. Domestically, the company will continue to focus on consumables and services and the delivery of year-end IT system deals, aiming for Q4 revenue comparable to the prior-year quarter. Overseas, while flat in yen terms, on a real basis results are expected to fall short of the previous forecast, particularly in North America and Asia/Other regions. The company will emphasize sales of in-house products in Q4 to secure a gross margin in the 52% range and curb the growth of SG&A, targeting higher revenue and profit.
Management emphasized earnings recovery and gross margin improvement in Q4 (securing the 52% range) and the restraint of SG&A. While budget restraints/deferrals domestically and distributor inventory adjustments are short-term headwinds, the company aims to recover in the second half through consumables and services and year-end deal deliveries. Overseas, although there are delays in regulatory compliance and a cautious stance in the decision process for patient monitor deals, the company plans to concentrate company-wide on shipping, delivery, and installation toward fiscal year-end. The special loss (2.4 billion yen in early retirement incentives) is a temporary factor, and the company aims to enhance medium- to long-term profitability through structural reforms.
Execution of company-wide earnings reform: Targeting a 0.8 ppt improvement in FY3/25 and a 2.5 ppt improvement in FY3/26 (+1.7 ppt YoY) by promoting SG&A reductions and workforce productivity gains. Stable growth of the domestic business: Capture replacement demand for medical equipment and maintain share; improve CX and contribute to medical safety through promotion of genuine consumables and expansion of maintenance services. Sustain high growth in North America: Expand market share in physiological measuring equipment (neuro and home sleep recorders), ventilators (new contracts with IDNs/GPOs), and patient monitors (differentiation via DHS products). Achieve the targets of the Medium-Term Management Plan (BEACON 2030 Phase II): Aim for sales CAGR of 5%, operating margin of 15%, and ROE of 12%, centered on strengthening product competitiveness, focusing on the North American business, company-wide earnings reform, and advancing the global supply chain. Clarify capital allocation policy: Balance investments for future corporate growth (approximately 23.5 billion yen in R&D, approximately 25.0 billion yen in capital expenditures, and over 30.0 billion yen in growth investments/M&A) with enhanced shareholder returns (over 28.0 billion yen in Phase II and a consolidated total payout ratio of 35% or more), while maintaining a sound financial base.
There is a risk that restraint and deferral of capital investment in medical equipment in Japan will progress more than expected, leading to results below the prior-year level, particularly at public hospitals. Prolonged inventory adjustments at AED distributors could pose a risk of a significant decline in unit sales from 63,800 units in the prior year to 58,100 units this year. In North America, caution in the decision-making process for patient monitor deals could pose a reversal risk from double-digit growth to results below the prior-year level. Delays in regulatory compliance in Asia/Other regions present a risk that shipments, delivery, and installation will be delayed toward fiscal year-end, as evidenced by results below the prior-year level in Q3. FX fluctuation risk (Q4 assumed rates of 154 yen/USD and 184 yen/EUR) could materially affect operating income, with FX gains/losses amplifying earnings volatility.